Vol.

No.

May 09, 2025May 09, 2025

DOWNLOAD THE PDF

Cover Story

Trump administration is removing the mainstays of NCI and the federal government’s cancer program

Peer review, registries, and evidence-based patient information take a big hit

By Paul Goldberg and Jacquelyn Cobb

How is the enterprise of cancer research doing after the first 100 days of the Trump administration?

Guest Editorial

George Weiner: Cancer centers are special, as are site visits in CCSG review

By George J. Weiner

Regulatory News

Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies

By Claire Marie Porter

Clinical Trials & Tribulations

Working with cancer: Rethinking long-term health for working-age adult cancer survivors

By Susan A. Speckhart, Rebecca Miksad and Lidia Schapira

Rewriting the rules of cancer treatment one nanobody at a time

By John D. Fryer

Free In the Archives

Walter Lawrence Jr.: “The National Cancer Act really gave us a lot of enthusiasm about the future.”

By Katie Goldberg

Cancer Policy

$180M in NCI grants have been terminated by Trump administration, systematic review finds

Bhattacharya cancels NIH all-hands meeting

NIH to update policies and practices, halting subawards to foreign entities

Women’s Health Initiative funding officially restored

AACR calls on Congress to reject Trump’s FY2026 budget request for NIH

PanCAN’s Julie Fleshman’s letter urges Congress to reject cuts to NIH

Twenty attorneys general sue Trump over “evisceration” of HHS

Scott Gottlieb, Mark McClellan warn of the major challenges created by planned reorganization of FDA

Trump signs order to boost domestic pharma manufacturing

First ODAC meeting since Trump’s inauguration scheduled for May 20-21

In last-minute switch, Trump taps Casey Means for surgeon general

In Brief

Timothy Swan elected ACR president, additional officers chosen

Cynthia Moran receives ACR Thorwarth Award for Radiology Leadership

Frank Minja, Toma Omofoye awarded ACR Foundation’s Global Humanitarian Award

NRG Oncology adds new committee leaders in lung cancer and imaging

Indonesia, CRUK Scotland Institute partner to advance cancer research

Funding Opportunities

CDMRP announces rare cancers research program funding opportunities for FY25

Clinical Roundup

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Durvalumab regimen demonstrates improvement in DFS for high-risk NMBIC in phase III trial

Zinc-transporting protein contributes to aggressive growth of brain tumor, study shows

Dxcover presents first real-world evidence that increased tumor size is associated with higher mortality in brain cancer

Drugs & Targets

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC

EU approves Calquence + chemo as first and only BTK inhibitor for first-line MLC

NCI Trials

NCI Trials for May 2025

The National Cancer Institute approved the following clinical research studies last month.

CURRENT ISSUE

Recent Issues